clinical trial · NCT06531798
Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease
AstraZeneca·phase4·recruiting·n = 150
Moderate to Severe COPDBreztri Aerosphere
brief summary
The purpose of this study is to observe the safety and tolerability of Breztri aerosphereTM as maintenance treatment in Indian patients with moderate to severe COPD.
started
Dec 19, 2025
primary completion
Oct 30, 2026
completion
Dec 30, 2027
last updated
Apr 20, 2026
detailed description
Study details include:
The study duration will be 26 weeks The treatment duration will be 24 weeks
official title
Post-marketing Phase IV, Multicenter, Prospective Study to Observe the Safety and Tolerability of Breztri aerosphereTM Containing a Fixed Dose Combination of Budesonide 160 mcg/ Glycopyrronium 7.2 mcg/ Formoterol Fumarate Dehydrate 5 mcg in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol